ELOX Overview

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Wall Street analysts forecast ELOX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELOX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Eloxx Pharmaceuticals Inc revenue for the last quarter amounts to NaN USD, decreased

Eloxx Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased

Eloxx Pharmaceuticals Inc (ELOX) has 0 emplpoyees as of June 10 2026.

Today ELOX has the market capitalization of 83.39M USD.